TN-1
Phase 2Small molecule
TN-1 is one of 25 small molecule programs targeting Breast Cancer. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
706 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Blenoxane
Bristol-Myers SquibbPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
TN-1
NNagoya City University
Phase 2
Neoadjuvant Treatment
SShanghai Zhongshan Hospital
Preclinical
Recombinant Human Endostatin
PPeking University Third Hospital
Preclinical
Tianeptine
PfizerPreclinical
Diuretic
RReprieve Cardiovascular, Inc
Preclinical
Bisphosphonate
AmgenPreclinical
Metfomin
UUniversity of Texas Southwestern Medical Center
Preclinical
Perflutren Lipid Microsphere
IImaRx Therapeutics
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TN-1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- NNagoya City University